Table 4.
Results of the biochemical evaluations.
| Biochemical analysis | Units | Placebo (N = 39) | CH-a (N = 38) | CH-b (N = 35) | |||
|---|---|---|---|---|---|---|---|
| Baseline | Week 16 | Baseline | Week 16 | Baseline | Week 16 | ||
| Blood urea | μmol L−1 | 9.5 ± 6.3 | 12.7 ± 6.5# | 7.9 ± 2.4 | 13.4 ± 4.0# | 8.3 ± 3.2 | 12.0 ± 3.7# |
| Uric acid | μmol L−1 | 267.3 ± 79.2 | 342.8 ± 85.9# | 304.4 ± 84.8 | 328.0 ± 88.5# | 281.3 ± 82.0 | 328.0 ± 88.5# |
| Serum creatinine | μmol L−1 | 86.3 ± 113.1 | 75.3 ±± 14.3 | 71.4 ± 12.7 | 78.0 ± 20.0 | 69.1 ± 13.1 | 73.8 ± 16.4 |
| Total bilirubin | μmol L−1 | 9.8 ± 5.5 | 12.8 ± 5.2# | 14.1 ±± 8.7 | 11.3 ± 5.8 | 11.9 ± 5.9 | 15.3 ± 15.4 |
| Direct bilirubin | μmol L−1 | 2.1 ± 0.8 | 2.8 ± 2.3# | 2.4 ± 1.2 | 3.1 ± 3.0 | 2.4 ± 1.0 | 3.1 ± 2.7 |
| SGOT | u L−1 | 23.4 ± 8.4 | 29.6 ± 7.5# | 24.2 ± 6.9 | 31.3 ±± 5.5# | 23.7 ± 7.9 | 29.3 ± 7.6# |
| SGPT | u L−1 | 20.7 ± 8.6 | 30.1 ± 8.5# | 22.7 ± 14.8 | 34.3 ± 8.6#* | 29.6 ± 37.5 | 32.3 ± 9.8 |
| ALP | u L−1 | 148.6 ± 57.0 | 197.2 ± 46.1# | 146.8 ± 42.2 | 185.0 ± 52.9# | 157.7 ± 53.3 | 185.0 ± 52.9# |
| Random blood glucose | mmol L−1 | 5.9 ± 1.3 | 7.0 ± 1.6# | 5.6 ± 1.2 | 7.1 ± 1.5# | 6.3 ± 2.7 | 6.9 ± 2.3 |
| Total cholesterol | mmol L−1 | 4.6 ± 0.8 | 4.4 ± 0.9 | 4.6 ± 0.9 | 4.5 ± 0.7 | 4.4 ± 0.8 | 4.3 ± 0.9 |
| Total protein | g L−1 | 72.0 ± 4.3 | 73.4 ± 6.5 | 71.3 ± 11.0 | 75.3 ± 12.8#* | 72.4 ± 5.6 | 74.4 ± 9.0 |
| Serum albumin | g L−1 | 41.9 ± 6.4 | 43.1 ± 5.9 | 41.8 ± 5.7 | 47.8 ± 6.5#* | 42.1 ± 6.0 | 45.2 ± 7.5# |
Data are expressed as mean ± SD values.
#P < 0.05 vs. baseline; *P < 0.05 vs. placebo.
SGOT, serum glutamic oxaloacetate; SGPT, serum glutamic pyruvate transaminase; ALP, alkaline phosphatase.